Silver Book Fact
It is imperative to weigh costs of implementing new technologies for predicting onset of Alzheimer’s disease through biomarkers and delaying onset earlier against the potential benefits of improving health. Overall the study finds that the value of increased longevity through these potential innovations will greatly exceed the rising costs of health care.
Vernon, John, Robert Goldberg, Yashodhara Dash, and Guruprasaadh Muralimohan. Alzheimer’s Disease and Cost-effectiveness Analyses: Ensuring good value for money?. Working Paper — Pending Publication; 2007. http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=12477